SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis
Abroad (travel likely)RecruitingPHASE1
Conditions
Relapsing Remitting Multiple Sclerosis · Primary Progressive Multiple Sclerosis · Secondary Progressive Multiple Sclerosis
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Royal London Hospital, Barts Health NHS Foundation Trust, London, Greater London, United Kingdom
Contact: Study coordinator (Sharmilee Gnanapavan, MD) · Sharmilee.gnanapavan@bartshealth.nhs.uk · +44 2073777000Contact: Study coordinator (Lucia Bianchi, PhD) · Lucia.bianchi@bartshealth.nhs.uk · +44 20 7882 2598Contact: Principal Investigator (Sharmilee Gnanapavan, MD)